Zucara Therapeutics Inc., a start-up company founded by The Centre for Drug Research and Development and TIAP (then MaRS Innovation), is developing the first once-daily therapeutic to prevent hypoglycemia in patients with diabetes. Preventing hypoglycemia will dramatically change diabetes disease management, thereby improving both patient health and quality of life.
In May 2021, Zucara successfully completed Phase I study showing that ZT-01 is safe and well-tolerated. See press release here